Filgotinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Phase III Randomised Clinical Trial
Ann Rheum Dis. 2021 Jan 27:annrheumdis-2020-219214
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 2021 Jan 27:annrheumdis-2020-219214
https://pubmed.ncbi.nlm.nih.gov/33549192/
Bimekizumab therapy was associated with a rapid and sustained improvement in PASI response and IGA score in patients with moderate to severe plaque psoriasis. Dual inhibition of IL-17A/F with bimekizumab can affect a more durable response in PsO patients than sole IL-17A inhibition. Gordon et al. compared the safety and efficacy of two different maintenance dosing schedules, in addition to the effects of treatment withdrawal in the 52-week BE READY trial.
Lancet 2021;397:487–98. doi: 10.1016/S0140-6736(21)00125-2
Bimekizumab was more efficacious than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis. Previous bimekizumab Phase 2 clinical studies have shown both rapid and durable clinical improvements in skin clearance, as well as a safety profile in line with expectations from this MoA. This study aimed to evaluate the efficacy and safety of bimekizumab in moderate to severe plaque PsO over 1 year compared with both placebo and ustekinumab.
Annals of the rheumatic diseases. 2021 Mar 1;80(3):312-20.
Please click the links below to go to the CSF review of each paper
RMD Open 2020;6:e001374 doi:10.1136/rmdopen-2020-001374
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-21841220
Ann Rheum Dis 2020 DOI:10.1136/annrheumdis-2020-218510
N Engl J Med 2020;383:1511–21 DOI: 10.1056/NEJMoa2008250
Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992